Reprogram Biosciences Inc.

Reprogram Biosciences, based in the US, is dedicated to developing innovative cancer treatment solutions that convert cancer cells into immune-like cells, enhancing the body’s ability to combat malignancies. Reprogram Biosciences Inc. specializes in advanced cancer therapies through reprogramming cancer cells. Founded in 2025, By Co-founders Rustam Esanov(CEO) and Eziz Kuliyev (COO).

the company is headquartered in San Carlos, US. In March 2026, Reprogram raised USD 5 million in Seed funding from investors including 1517 Fund, Narya, and Unshackled Ventures. Reprogram Biosciences specializes in innovative cancer treatment solutions through its core product offerings, which focus on reprogramming cancer cells into immune-like cells within patients. The company employs a novel therapeutic gene cocktail delivered via a cutting-edge lipid nanoparticle system, enabling precision targeting of solid tumors.

This transformative immunotherapy approach empowers the body’s immune system to combat cancer more effectively and affordably, directly addressing the critical need for advanced treatment modalities in oncology. Reprogram Biosciences aims to provide these services primarily to healthcare institutions and oncology clinics across North America and Europe, targeting a wide range of solid tumors. The end users of these treatments include cancer patients seeking novel therapies with the potential for improved outcomes compared to traditional approaches. Reprogram Biosciences generates revenue through direct partnerships with healthcare providers, oncology clinics, and research institutions that adopt its innovative therapeutic solutions.

The company's transactions are structured around the provision of its flagship gene reprogramming therapies, which are offered as ready-to-use treatments for solid tumors. Clients may engage in agreements that involve purchasing treatment packages tailored to specific cancer types, facilitating streamlined access to cutting-edge immunotherapies. The pricing structure reflects the advanced nature of the therapies, encompassing costs associated with the proprietary gene reprogramming technologies and lipid nanoparticle delivery systems. Overall, the company's revenue model emphasizes collaboration with healthcare entities to facilitate the adoption and distribution of its transformative cancer treatments.

In March 2026, Reprogram Biosciences Inc. raised USD 5 million in Seed funding to support its future growth initiatives. The company is focusing on developing new treatment products aimed at enhancing its therapeutic offerings in oncology. Plans include expanding its market reach into regions across Europe and North America by the end of 2027.

The recent funding will be utilized to accelerate product development and facilitate entry into these new markets.